These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
278 related articles for article (PubMed ID: 15531127)
1. Effects of progestins on estrogen-induced increase in C-reactive protein in postmenopausal women. Rossi R; Bursi F; Veronesi B; Cagnacci A; Modena MG Maturitas; 2004 Dec; 49(4):315-20. PubMed ID: 15531127 [TBL] [Abstract][Full Text] [Related]
2. Effects of intranasal 17beta-estradiol administration on serum bioactive interleukin-6 and C-reactive protein levels in healthy postmenopausal women. Rachoń D; Suchecka-Rachoń K; Hak Ł; Myśliwska J Menopause; 2006; 13(5):840-5. PubMed ID: 16894332 [TBL] [Abstract][Full Text] [Related]
3. Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: a review article. Lakoski SG; Herrington DM Climacteric; 2005 Dec; 8(4):317-26. PubMed ID: 16390766 [TBL] [Abstract][Full Text] [Related]
4. Progestins affect mechanism of estrogen-induced C-reactive protein stimulation. Reuben DB; Palla SL; Hu P; Reboussin BA; Crandall C; Herrington DM; Barrett-Connor E; Greendale GA Am J Med; 2006 Feb; 119(2):167.e1-8. PubMed ID: 16443423 [TBL] [Abstract][Full Text] [Related]
5. Comparative cardiovascular effects of different progestins in menopause. Rosano GM; Fini M Int J Fertil Womens Med; 2001; 46(5):248-56. PubMed ID: 11720197 [TBL] [Abstract][Full Text] [Related]
6. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels. Gol M; Akan P; Dogan E; Karas C; Saygili U; Posaci C Maturitas; 2006 Feb; 53(3):252-9. PubMed ID: 15990257 [TBL] [Abstract][Full Text] [Related]
7. The effect of the phytoestrogen genistein and hormone replacement therapy on homocysteine and C-reactive protein level in postmenopausal women. D'Anna R; Baviera G; Corrado F; Cancellieri F; Crisafulli A; Squadrito F Acta Obstet Gynecol Scand; 2005 May; 84(5):474-7. PubMed ID: 15842212 [TBL] [Abstract][Full Text] [Related]
8. Breast cancer risk with postmenopausal hormonal treatment. Collins JA; Blake JM; Crosignani PG Hum Reprod Update; 2005; 11(6):545-60. PubMed ID: 16150813 [TBL] [Abstract][Full Text] [Related]
9. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Psaty BM; Heckbert SR; Atkins D; Lemaitre R; Koepsell TD; Wahl PW; Siscovick DS; Wagner EH Arch Intern Med; 1994 Jun; 154(12):1333-9. PubMed ID: 8002685 [TBL] [Abstract][Full Text] [Related]
10. Effects of hormone replacement therapy on insulin resistance and platelet function tests. Saraç F; Saydam G; Sahin F; Oztekin K; Saygili F; Tüzün M; Yilmaz C Med Princ Pract; 2009; 18(1):43-7. PubMed ID: 19060490 [TBL] [Abstract][Full Text] [Related]
11. Effect of estrogen-progestin and estrogen on mammographic density. Kaewrudee S; Anuwutnavin S; Kanpittaya J; Soontrapa S; Sakondhavat C J Reprod Med; 2007 Jun; 52(6):513-20. PubMed ID: 17694969 [TBL] [Abstract][Full Text] [Related]
12. The effects of hormone replacement therapy on antithrombin III and protein C levels in menopausal women. Lacroix KA; Bean C; Reilly R; Curran-Celentano J Clin Lab Sci; 1997; 10(3):145-8. PubMed ID: 10167774 [TBL] [Abstract][Full Text] [Related]
13. Estrogen and estrogen-androgen replacement in postmenopausal women dissatisfied with estrogen-only therapy. Sexual behavior and neuroendocrine responses. Sarrel P; Dobay B; Wiita B J Reprod Med; 1998 Oct; 43(10):847-56. PubMed ID: 9800666 [TBL] [Abstract][Full Text] [Related]
14. Genetic variation in estrogen receptor, C-reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. de Maat MP; Madsen JS; Langdahl B; Bladbjerg EM; Tofteng CL; Abrahamsen B; Rejnmark L; Brixen K; Christensen K; Jespersen J; Kristensen SR Thromb Haemost; 2007 Feb; 97(2):234-9. PubMed ID: 17264952 [TBL] [Abstract][Full Text] [Related]
15. Physical activity, body fat, and serum C-reactive protein in postmenopausal women with and without hormone replacement. Manns PJ; Williams DP; Snow CM; Wander RC Am J Hum Biol; 2003; 15(1):91-100. PubMed ID: 12552583 [TBL] [Abstract][Full Text] [Related]
16. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels. Pluchino N; Genazzani AD; Bernardi F; Casarosa E; Pieri M; Palumbo M; Picciarelli G; Gabbanini M; Luisi M; Genazzani AR Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353 [TBL] [Abstract][Full Text] [Related]
17. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women. van Baal WM; Kenemans P; van der Mooren MJ; Kessel H; Emeis JJ; Stehouwer CD Thromb Haemost; 1999 Jun; 81(6):925-8. PubMed ID: 10404769 [TBL] [Abstract][Full Text] [Related]
18. Effects of hormone replacement therapy regimens on mammographic breast density: the role of progestins. Topal NB; Ayhan S; Topal U; Bilgin T J Obstet Gynaecol Res; 2006 Jun; 32(3):305-8. PubMed ID: 16764621 [TBL] [Abstract][Full Text] [Related]
19. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. Grodstein F; Stampfer MJ; Manson JE; Colditz GA; Willett WC; Rosner B; Speizer FE; Hennekens CH N Engl J Med; 1996 Aug; 335(7):453-61. PubMed ID: 8672166 [TBL] [Abstract][Full Text] [Related]
20. Short-term effects of hormone therapy on serum C-reactive protein levels in postmenopausal women. Kiran H; Kiran G Arch Gynecol Obstet; 2006 Apr; 274(1):9-12. PubMed ID: 16369811 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]